Effects of ramucirumab injection: A Synthesis of Findings from 4 Studies

  1. Home
  2. Effects of ramucirumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ramucirumab injection: A Synthesis of Findings from 4 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ramucirumab injection: A Synthesis of Findings from 4 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Ramucirumab, along with other monoclonal antibodies like nivolumab, is used to treat advanced gastric cancer (AGC). 3 . AGC patients often experience malignant ascites, which occurs alongside peritoneal metastasis. However, the distribution of these therapeutic monoclonal antibodies into ascites remains insufficiently investigated. 3 . In a global Phase III RELAY study, ramucirumab combined with erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) compared to placebo plus erlotinib (PL + ERL) in patients with EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC). 4 . This study's analysis focused on the East Asian subset of patients. 4 . The presence of large amounts of ascites can influence the pharmacokinetics of ramucirumab, as shown in a study analyzing patients with gastrointestinal cancers. 2 These findings emphasize the need for further investigation into the distribution of ramucirumab and other therapeutic monoclonal antibodies into ascites to potentially enhance treatment outcomes.

Benefits and Risks

Benefits Summary

Ramucirumab combined with erlotinib significantly improved progression-free survival (PFS) compared to placebo plus erlotinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC). 4

Risks Summary

Ramucirumab was associated with a higher frequency of grade 3 or higher treatment-emergent adverse events, and a slightly higher rate of treatment discontinuation due to adverse events compared to placebo. 4

Study Comparisons

Similarities Between Studies

These studies all focused on evaluating the pharmacokinetics and efficacy of ramucirumab and other therapeutic monoclonal antibodies.

Differences Between Studies

These studies varied in the disease they focused on, their study designs, and evaluation criteria. For instance, 3 involved a case report and literature review focused on the distribution of ramucirumab into ascites in patients with advanced gastric cancer. 4 was a Phase III clinical trial that assessed the efficacy and safety of ramucirumab combined with erlotinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer. 2 conducted a population pharmacokinetic analysis to explore the influence of massive ascites on ramucirumab's pharmacokinetics in patients with gastrointestinal cancers.

Consistency and Contradictions in Results

These studies collectively provide valuable information about the efficacy and safety of ramucirumab. However, further research is needed to better understand the distribution of ramucirumab into ascites and how this distribution might affect its therapeutic effectiveness. While these studies investigated the pharmacokinetics and efficacy of ramucirumab, they didn't always arrive at identical conclusions.

Considerations for Real-World Application

The findings from these studies offer crucial insights into the efficacy and safety of ramucirumab. It's important to remember that these studies were conducted on specific patient populations, and their outcomes may not be universally applicable to all individuals. Patients considering ramucirumab therapy should consult with their healthcare providers to discuss their individual situation and determine the most appropriate treatment option.

Limitations of Current Research

These studies have certain limitations. For instance, 3 is a case report and literature review, making its findings less generalizable. Additionally, 4 was conducted on a specific patient population, and its results may not apply to everyone. Moreover, 2 is a pharmacokinetic analysis, and further research is needed to understand its clinical significance.

Future Research Directions

Based on these research findings, it's crucial to further evaluate the distribution of ramucirumab into ascites and its impact on treatment effectiveness. Efforts should also focus on discovering ways to enhance ramucirumab's therapeutic outcomes. Future studies should investigate the pharmacokinetics and efficacy of ramucirumab using larger sample sizes, more diverse patient populations, and longer follow-up periods.

Conclusion

Ramucirumab combined with erlotinib demonstrated significantly improved progression-free survival (PFS) compared to placebo plus erlotinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC). 4 . However, additional research is needed to fully understand the distribution of ramucirumab into ascites and its influence on therapeutic efficacy. Individuals considering ramucirumab treatment should consult with their healthcare provider to discuss their unique situation and determine the most suitable treatment plan.

Literature analysis of 4 papers
Positive Content
3
Neutral Content
1
Negative Content
0
Article Type
2
0
0
1
4
1.

A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.

Author: KarbwangJ, DavisT M, LooareesuwanS, MoluntoP, BunnagD, WhiteN J

Treats malaria
Hypotension
Prolonged QTc interval

Quinine and quinidine, both antimalarial drugs, have different pharmacokinetic profiles. Quinidine has a shorter elimination half-time and is less bound to plasma proteins than quinine. Both drugs can prolong the QTc interval.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis.

Author: KanekoTakuya, DokiKosuke, YamadaTakeshi, YamamotoYoshiyuki, MoriwakiToshikazu, SuzukiYoshiharu, HommaMasato

Higher clearance
Lower concentration

This study investigated the impact of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers. It found that massive ascites significantly increased ramucirumab clearance and resulted in lower trough concentrations. This suggests that dose optimization of ramucirumab may be necessary in patients with massive ascites.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review.

Author: KanekoTakuya, DokiKosuke, YamadaTakeshi, YamamotoYoshiyuki, MoriwakiToshikazu, SuzukiYoshiharu, HommaMasato

Treats gastric cancer

This study investigated the distribution of therapeutic monoclonal antibodies, including ramucirumab and nivolumab, into ascites in patients with advanced gastric cancer (AGC). It aimed to assess the extent to which these antibodies reach the peritoneal cavity in AGC patients.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Author: NishioMakoto, SetoTakashi, ReckMartin, GaronEdward B, ChiuChao-Hua, YohKiyotaka, ImamuraFumio, ParkKeunchil, ShihJin-Yuan, Visseren-GrulCarla, Frimodt-MollerBente, ZimmermannAnnamaria, HommaGosuke, EnatsuSotaro, NakagawaKazuhiko,

Superior progression-free survival
Adverse events

This analysis of the RELAY study evaluated the efficacy and safety of ramucirumab plus erlotinib (RAM + ERL) in patients with EGFR mutation-positive metastatic non-small-cell lung cancer (NSCLC) in East Asia. RAM + ERL demonstrated superior progression-free survival (PFS) compared to placebo plus erlotinib (PL + ERL), with a median PFS of 19.4 months versus 12.5 months. While RAM + ERL had higher rates of grade ≥3 adverse events (70.7% versus 49.4%), the discontinuation rates and post-progression EGFR T790M mutation rates were similar between the two groups.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.